Sector News

Bayer eyes new corporate structure by Jan 2016

February 13, 2015
Life sciences
(Reuters) – German healthcare group Bayer has started working on a new corporate set-up for the life-science businesses that will remain when its plastics division is split off, aiming for a new structure at the beginning of next year.
 
Employees were informed on Wednesday that a team had been set up to map out the new structure, which will not entail job cuts, a spokesman said on Thursday.
 
“We expect the number of jobs to be stable worldwide and in Germany over the next few years,” he added.
 
Bayer, whose products include cancer drugs, birth control pills, veterinary drugs, pesticides and transparent plastics, unveiled plans in September to list its plastics business on the stock market to focus on its more profitable life-science businesses.
 
It said at the time it was eyeing a spin-off or initial public offering of the MaterialScience unit within 12-18 months.
 
Its three main divisions HealthCare, CropScience and MaterialScience each have largely autonomous management teams but the company has recently stressed the synergies to be gained in the research into human, animal and plant health. (Reporting by Ludwig Burger; Editing by Mark Potter)

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.